Perrigo Amends & Restates Credit Agreement, Securing $1.0B Revolving Facility Until 2031
summarizeSummary
Perrigo has amended and restated its credit agreement, securing a new $1.0 billion revolving credit facility with an extended maturity to 2031 and maintaining a $972.4 million term loan B facility, providing critical liquidity and financial flexibility.
check_boxKey Events
-
Amended & Restated Credit Agreement
Perrigo Company plc entered into an Amended and Restated Credit Agreement on March 20, 2026, replacing an existing agreement from April 20, 2022.
-
New Credit Facilities Established
The agreement establishes a $1.0 billion revolving credit facility maturing on March 20, 2031, and maintains a $972.4 million term loan B facility maturing on April 20, 2029.
-
Refinancing of Existing Debt
Proceeds from the new revolving facility will be used to prepay existing Term A Loans in their entirety.
-
Improved Borrowing Terms
The amendment eliminates the credit spread adjustment applicable to loans under the Revolving Facility, potentially reducing borrowing costs.
auto_awesomeAnalysis
Perrigo has amended and restated its credit agreement, establishing a new $1.0 billion revolving credit facility maturing in March 2031 and maintaining a $972.4 million term loan B facility. This is a significant development for the company, especially in light of its reported $1.43 billion net loss for 2025 and anticipated further impairments. The extension of the revolving facility's maturity provides crucial liquidity and extends the company's financial runway, addressing near-term capital structure risks. The elimination of the credit spread adjustment for the revolving facility also suggests more favorable borrowing terms. The proceeds will be used for refinancing existing Term A Loans, working capital, and general corporate purposes, which are vital for a company navigating financial challenges.
At the time of this filing, PRGO was trading at $9.69 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $9.23 to $28.44. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.